Open AccessPooled Human Immunoglobulin Therapy in Critically Ill Patients With Pandemic 2009 Influenza A(H1N1) Pneumonitis and Immunoglobulin G2 Subclass (IgG2) Deficiency
Author(s) -
Claire L. Gordon,
Katherine M. Langan,
P. G. P. Charles,
Rinaldo Bellomo,
Graeme K. Hart,
Joseph Torresi,
P. D. R. Johnson,
M. Lindsay Grayson
Publication year - 2010
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciq082
Subject(s) - medicine , subclass , pandemic , critically ill , immunology , antibody , pneumonia , immunoglobulin g , pneumonitis , covid-19 , virology , intensive care medicine , infectious disease (medical specialty) , lung , disease
To the Editor—We have previously reported an association between IgG2 deficiency and severe H1N1 infection [1]. We now describe 5 such patients who were failing antiviral therapy and were treated with intravenous immunoglobulin (IVIG) as potential salvage therapy. The patient clinical characteristics, laboratory features, treatment, tolerability, and overall outcomes are described in Table 1. All patients had known risk factors for severe H1N1 infection (pregnancy, n 5 2; asthma, n 5 1; obesity and asthma, n 5 1; chronic lymphocytic leukemia plus high-dose corticosteroids, n 5 1). All patients required mechanical ventilation (mean, 19 days; range, 5–38 days) and 3 required extracorporeal membrane oxygenation (ECMO; mean, 13 days; range, 9–17 days). IVIG was administered after mean illness duration
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom